['homozygous familial hypercholesterolemia']
['evinacumab', 'placebo']

        Key Inclusion Criteria:

          1. Diagnosis of functional HoFH

          2. If undergoing LDL apheresis, must have initiated LDL apheresis at least 3 months prior
             to screening and must have been on a stable weekly or every other week schedule and/or
             stable settings for at least 8 weeks

          3. Willing to consistently maintain his/her usual low fat or heart-healthy diet for the
             duration of the study

        Key Exclusion Criteria:

          1. LDL-C level <70 mg/dL (1.81 mmol/L) at the screening visit

          2. Background medical Lipid Modifying Therapy (LMT) (if applicable) that has not been
             stable before the screening visit

          3. Lipid-apheresis schedule /apheresis settings (if applicable) that have not been stable
             for at least 8 weeks before the screening visit

          4. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a
             dose/amount that has not been stable for at least 4 weeks prior to the screening visit

          5. Presence of any clinically significant uncontrolled endocrine disease known to
             influence serum lipids or lipoproteins

          6. Newly diagnosed (within 3 months prior to randomization visit) diabetes mellitus or
             poorly controlled (HbA1c >9%) diabetes

          7. History of a MI, unstable angina leading to hospitalization, coronary artery bypass
             graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia,
             carotid surgery or stenting, stroke, transient ischemic attack, valve replacement
             surgery, carotid revascularization, endovascular procedure or surgical intervention
             for peripheral vascular disease within 3 months prior to the screening visit

          8. Pregnant or breastfeeding women

          9. Sexually active women of child bearing potential (WOCBP), who are unwilling to
             practice a highly effective birth control method prior to the initial dose, during the
             study, and for 24 weeks after the last dose of study drug

         10. Men who are sexually active with women of child bearing potential (WOCBP) and are
             unwilling to consistently use condoms during the study drug treatment period and for
             24 weeks after the last dose of study drug regardless of vasectomy status

        Note: Other protocol defined inclusion/exclusion criteria may apply.
      